Gilead Sciences, Inc. (GILD)

NASDAQ: GILD · IEX Real-Time Price · USD
86.26
+0.84 (0.98%)
At close: Nov 25, 2022 1:00 PM
85.81
-0.45 (-0.52%)
After-hours: Nov 25, 2022 4:29 PM EST
0.98%
Market Cap 107.14B
Revenue (ttm) 27.14B
Net Income (ttm) 3.33B
Shares Out 1.26B
EPS (ttm) 2.64
PE Ratio 32.67
Forward PE 12.69
Dividend $2.90 (3.36%)
Ex-Dividend Date Dec 14, 2022
Volume 3,992,089
Open 85.04
Previous Close 85.42
Day's Range 84.76 - 86.41
52-Week Range 57.17 - 86.41
Beta 0.44
Analysts Buy
Price Target 77.34 (-10.3%)
Earnings Date Oct 27, 2022

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, T... [Read more]

Industry Biotechnology
IPO Date Jan 22, 1992
CEO Daniel O'Day
Employees 14,400
Stock Exchange NASDAQ
Ticker Symbol GILD
Full Company Profile

Financial Performance

In 2021, GILD's revenue was $27.31 billion, an increase of 10.60% compared to the previous year's $24.69 billion. Earnings were $6.23 billion, an increase of 4,960.98%.

Financial Statements

Analyst Forecast

According to 37 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is 77.34, which is a decrease of -10.34% from the latest price.

Price Target
$77.34
(-10.34% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Pick These 4 Stocks With Exciting Interest Coverage Ratio

A company capable of generating earnings well above its interest expense can withstand financial hardship. General Mills (GIS), Texas Roadhouse (TXRH), O'Reilly Automotive (ORLY) and Gilead Sciences (GI...

Other symbols: GISORLYTXRH
23 hours ago - Zacks Investment Research

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

2 days ago - Zacks Investment Research

See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch

Gilead Sciences' first-in-class cancer drug and GILD stock are finally hitting their stride. The oncology business is growing bullishly.

3 days ago - Investors Business Daily

Is it too late to invest in the Biotech stocks?

“IBB” – the iShares Biotechnology ETF has already recovered about 30% over the past five months but Jefferies' Michael Yee is convinced it still has more room to the upside. Yee's bull case for the biot...

3 days ago - Invezz

Buy this Medical Sector Pioneer Stock

Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.

3 days ago - Zacks Investment Research

GILD vs. HALO: Which Stock Is the Better Value Option?

GILD vs. HALO: Which Stock Is the Better Value Option?

Other symbols: HALO
3 days ago - Zacks Investment Research

Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?

Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.

1 week ago - Zacks Investment Research

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.

1 week ago - Zacks Investment Research

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:

1 week ago - Business Wire

2 Top Biotech Stocks to Buy in November

Both of these companies have potential catalysts on the way.

Other symbols: REGN
1 week ago - The Motley Fool

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

2 weeks ago - Zacks Investment Research

Has This Hot Stock Run Out of Steam?

Shares of Gilead Sciences have been have been on a tear recently.

2 weeks ago - The Motley Fool

Why Shares of Gilead Sciences Rose 27.20% in October

The company's growing oncology portfolio is driving increased revenues.

2 weeks ago - The Motley Fool

Gilead, Kite in process of pausing Twitter advertising

Gilead Sciences Inc said on Monday the company and its unit Kite were in the "process of pausing advertising" on Twitter, after Elon Musk completed his takeover of the social media company.

Other symbols: TWTR
2 weeks ago - Reuters

3 No-Brainer Dividend Stocks to Buy in November

There's no need for agonizing decision-making with these great dividend stocks.

Other symbols: ABBVJNJ
3 weeks ago - The Motley Fool

Should I buy Gilead Sciences shares in November 2022?

Gilead Sciences, Inc. (NASDAQ: GILD) shares have advanced from $61.45 to $80 since the beginning of October 2022, and the current price stands at $79.46. Gilead Sciences reported better-than-expected th...

3 weeks ago - Invezz

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

3 weeks ago - Zacks Investment Research

Gilead stock is not out of room to run just yet: Truist

Gilead Sciences Inc (NASDAQ: GILD) ended this week up nearly 20% after reporting its quarterly results that handily topped Street estimates and subsequently winning an upgrade from a Truist analyst. Gil...

3 weeks ago - Invezz

These 2 Stock Winners Topped Apple's Big Gains Friday

Strong earnings helped lift the market.

Other symbols: KNSL
4 weeks ago - The Motley Fool

Gilead Sciences stock surges amid earnings beat and analyst upgrades

Shares of Gilead Sciences are getting a boost thanks to strong earnings for its third quarter.

4 weeks ago - Yahoo Finance

Truist: Buy this undervalued biotech stock

The "Halftime Report" traders debate the biggest analyst calls of the day

4 weeks ago - CNBC Television

Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised

Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.

4 weeks ago - Zacks Investment Research